Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px
Document › Details

Lonza Group AG. (8/4/17). "Press Relase: Lonza Prices EUR 700 Million and USD 200 Million Multi Tranche »Schuldschein« Loan". Basel.

Organisations Organisation Lonza Group AG
  Today Lonza Group (Group)
  Group Lonza Group (Group)
  Organisation 2 Commerzbank AG
  Group Commerzbank (Group)
Products Product investment banking
  Product 2 contract manufacturing (drugs)
Index term Index term Kohlberg Kravis Roberts–Lonza: investment, 201612–201707 acquisition of Capsugel for $5.5b in cash from KKR by Lonza
Persons Person Oehlers, Dirk (Lonza 201610 Head Investor Relations)
  Person 2 Werner, Dominik (Lonza 201610 Head Corporate Communications)
     


Lonza Group Ltd, Basel (“Lonza”), today announced the pricing of its multitranche "Schuldschein" loan (private placement) with a total size of EUR 700 million and USD 200 million at competitive market terms. The EUR tranches have maturities of 4 and 6 years respectively with fixed and variable coupons. The USD tranches have maturities of 5 (variable coupon) and 7 years (fixed coupon).

The proceeds of the “Schuldschein” loan will be used for the refinancing of the Capsugel acquisition. Commerzbank, Helaba, HSBC, ING Bank, and LBBW have jointly acted as arrangers of the “Schuldschein” loan.


About Lonza

Following the closing of the Capsugel acquisition, Lonza further strengthened its position as one of the world’s
leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. Lonza harnesses
science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

An integrated solutions provider serving the healthcare continuum, Lonza offers products and services from the
custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. In addition to drinking water sanitizers, nutraceuticals, antidandruff agents and other personal care ingredients, the company provides agricultural products, advanced coatings and composites and microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a wellrespected global company with more than 50 major manufacturing and R&D facilities and nearly 14,000 full-time employees worldwide. Further information can be found at www.lonza.com.


Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary
listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the
SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in
this news release.


Lonza Contact Details

Dirk Oehlers, Head Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540
dirk.oehlers@lonza.com

Dr Kristin Köhler, Senior Manager Investor Relations
Lonza Group Ltd
Tel +41 61 316 8782
kristin.koehler@lonza.com

Dominik Werner, Head Corporate Communications
Lonza Group Ltd
Tel +41 61 316 8798
dominik.werner@lonza.com

Constance Ward, Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840
constance.ward@lonza.com

Lonza Ltd
Muenchensteinerstrasse 38
CH-4002 Basel, Switzerland
+41 61 316 81 11
+41 61 316 91 11
media@lonza.com

   
Record changed: 2017-08-10

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 600x80px

More documents for Lonza Group (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px